Scholarlink

Background <p>The importance of quality of life (QoL) in cancer care has gained increasing recognition, but no scale for renal cancer was developed based on the modular approach. This paper is aimed to develop and validate a renal cancer-specific assessment tool, QLICP-RE (V2.0), to provide a scientific basis for evaluating the QoL of kidney cancer patients and informing relevant policy development.</p> Methods <p>The QLICP-RE (V2.0) was developed based on procedural decision-making methods and combining the general module and the specific module. Based on the data from 179 admitted and discharged renal cancer patients, the psychometric properties of the scale were evaluated. Reliability of the QLICP-RE (V2.0) was evaluated using Cronbach’s α and Test-retest reliability correlation. The construct validity and criteria-related validity was assessed through correlation analysis and structural equation modeling. The responsiveness was evaluated by comparing the differences in scores of the scale before and after treatment using paired t-tests, and computing the Standard Response Mean (SRM).</p> Results <p>The QLICP-RE(V2.0) was developed with a 32 items general module and a 11 items specific module. Regarding the Cronbach’s α coefficients for each domain of the QLICP-RE (V2.0), all domains showed satisfactory reliability (α ≥ 0.7), except for the social functioning domain (α = 0.34). The test-retest reliability coefficients demonstrated good stability, with values exceeding 0.80 for all domains except the social functioning domain (<i>r</i> = 0.50). The correlation analysis and structural equation modeling confirmed good construct validity and criterion-related validity. There were significant differences (<i>P</i> &lt; 0.05) for all domains exception of psychological function and common symptoms and side effects, and also specific module and the total scale before and after treatments, with standardized response mean (SRM) values ranged from − 2.54 to 0.23.</p> Conclusion <p>QLICP-RE(V2.0) has good validity, reliability and moderate responsiveness. In the future, more patients should be enrolled and the sample size should be expanded to continuously optimize the scale and evaluate the quality of life of patients with renal cancer more scientifically.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and validation of the renal cancer scale among the system of quality of life instruments for cancer patients QLICP-RE (V2.0): a multicenter longitudinal study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Chuanzhi Xu,
  • Chenyao Li,
  • Liren Hu,
  • Shengjie Guo,
  • Jiayuan Wu,
  • Jingjing Zhang,
  • Fengbo Guo,
  • Chonghua Wan

摘要

Background

The importance of quality of life (QoL) in cancer care has gained increasing recognition, but no scale for renal cancer was developed based on the modular approach. This paper is aimed to develop and validate a renal cancer-specific assessment tool, QLICP-RE (V2.0), to provide a scientific basis for evaluating the QoL of kidney cancer patients and informing relevant policy development.

Methods

The QLICP-RE (V2.0) was developed based on procedural decision-making methods and combining the general module and the specific module. Based on the data from 179 admitted and discharged renal cancer patients, the psychometric properties of the scale were evaluated. Reliability of the QLICP-RE (V2.0) was evaluated using Cronbach’s α and Test-retest reliability correlation. The construct validity and criteria-related validity was assessed through correlation analysis and structural equation modeling. The responsiveness was evaluated by comparing the differences in scores of the scale before and after treatment using paired t-tests, and computing the Standard Response Mean (SRM).

Results

The QLICP-RE(V2.0) was developed with a 32 items general module and a 11 items specific module. Regarding the Cronbach’s α coefficients for each domain of the QLICP-RE (V2.0), all domains showed satisfactory reliability (α ≥ 0.7), except for the social functioning domain (α = 0.34). The test-retest reliability coefficients demonstrated good stability, with values exceeding 0.80 for all domains except the social functioning domain (r = 0.50). The correlation analysis and structural equation modeling confirmed good construct validity and criterion-related validity. There were significant differences (P < 0.05) for all domains exception of psychological function and common symptoms and side effects, and also specific module and the total scale before and after treatments, with standardized response mean (SRM) values ranged from − 2.54 to 0.23.

Conclusion

QLICP-RE(V2.0) has good validity, reliability and moderate responsiveness. In the future, more patients should be enrolled and the sample size should be expanded to continuously optimize the scale and evaluate the quality of life of patients with renal cancer more scientifically.